Assessment of the impact of weekly versus monthly erythropoiesis stimulating protein therapy on patients with CKD and their families.
نویسندگان
چکیده
This cross-sectional study measured patient and family member reported treatment and economic burden associated with monthly versus weekly erythropoiesis stimulating protein therapies for anemia in patients with CKD who were not yet on dialysis. The results indicated that compared to a weekly regimen, a monthly regimen saved patients 7 hours and family members 19 hours per month for routine anemia management. The monthly regimen substantially reduced the reported economic and treatment burdens of patient and their family members.
منابع مشابه
Recombinant human epoetin beta in the treatment of renal anemia
Cardiovascular disease is the leading cause of the poor long-term survival of patients with chronic kidney disease (CKD). Anemia complicating CKD not only impairs patients' quality of life, but is also an independent risk factor for adverse cardiovascular outcomes. The availability of recombinant human erythropoietin (rHuEPO) has greatly changed the management of anemia in CKD patients. Besides...
متن کاملOutcomes in patients with chronic kidney disease not on dialysis receiving extended dosing regimens of darbepoetin alfa: long-term results of the EXTEND observational cohort study
BACKGROUND Extended dosing of the erythropoiesis-stimulating agent (ESA) darbepoetin alfa (DA) once biweekly or monthly reduces anaemia treatment burden. This observational study assessed outcomes and dosing patterns in patients with chronic kidney disease not on dialysis (CKD-NoD) commencing extended dosing of DA. METHODS Adult CKD-NoD patients starting extended dosing of DA in Europe or Aus...
متن کاملAssessment of time and practice resources required to provide weekly or monthly erythropoiesis-stimulating protein therapy to chronic kidney disease patients in the physician office setting.
BACKGROUND There is an epidemic of chronic kidney disease (CKD) and a high prevalence of anemia (47%) observed in CKD patients. Little is known about the cost in physician office resources of routine erythropoiesis-stimulating protein (ESP) administration to treat patients with nondialysis CKD. OBJECTIVES The objectives of this research were (1) to explore the patterns of care in physician of...
متن کاملRestricted Use of Erythropoiesis-Stimulating Agent is Safe and Associated with Deferred Dialysis Initiation in Stage 5 Chronic Kidney Disease
The effect of erythropoiesis-stimulating agent (ESA) on dialysis initiation in advanced chronic kidney disease (CKD) patients is not clear. We retrospectively analyzed the outcome of dialysis initiation in a stage 5 CKD cohort with ESA reimbursement limited to the maximal standardized monthly ESA dose equivalent to epoetin beta 20,000 U by the National Health Insurance program. Totally 423 pati...
متن کاملEffectiveness of Acceptance and Commitment Therapy on Resiliency, Meaning of Life and Family Functioning In Caregivers of Patients With Schizophrenia
Aims: The caring of schizophrenia patients is a boring for their families. The aim of present study was to consider the effectiveness acceptance and commitment therapy on resiliency, meaning in life and family functioning in caregivers of patients with schizophrenia. Method: Research design was Quist -experimental in the form of pre-test, post-test and control group follow-up. The sample of...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
عنوان ژورنال:
- Nephrology nursing journal : journal of the American Nephrology Nurses' Association
دوره 34 2 شماره
صفحات -
تاریخ انتشار 2007